C

CenExel Clinical Research | Advanced Memory Research Institute of New Jersey

Research site
(Unclaimed)
Location
9 Mule Road, Toms River, New Jersey, United States of America
Site insights

Top conditions

Alzheimer Disease (14 trials)

Dementia (4 trials)

Disease Progression (1 trial)

Amyloidosis (1 trial)

Cognitive Dysfunction (1 trial)

Top treatments

Lanabecestat
LY3314814
LY3002813
Donanemab
Remternetug
Piromelatine
Solanezumab
AR1001
Aducanumab
Lecanemab

Parent organization

This site is a part of CenExel Clinical Research

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

6 of 14
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's...

Active, not recruiting
Alzheimer Disease
Drug: LY3372689
Drug: Placebo

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's d...

Enrolling
Alzheimer's Disease
Drug: Remternetug (SC)
Drug: Placebo

The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to e...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: AR1001

Randomized efficacy and safety study of piromelatine 20 mg versus placebo in participants with mild dementia due to Alzheimer's disease (AD) who are...

Active, not recruiting
Alzheimer's Disease
Drug: Piromelatine 20 mg
Drug: Placebo

Trial sponsors

Lilly logo

Lilly (8 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems